Tezcan Gulçin, Gurel Cigdem Bayram, Tutluoglu Bulent, Onaran Ilhan, Kanigur-Sultuybek Gonul
Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
J Asthma. 2009 May;46(4):371-4. doi: 10.1080/02770900902777791.
It has been suggested that inhibition of poly (ADP-ribose) polymerase-1 (PARP-1), either pharmacologically or by a gene knockout provides significant protection against systemic or tissue inflammation in animal models. The aim of this study was to analyze the association of the PARP-1 Val762Ala polymorphism, which has beenreported to be associated with decreased enzymatic activity, in Turkish patients with adult asthma.
A total of 112 subjects with stable asthma and 180 normal controls from the same geographic region were studied and polymerase chain reaction-based restriction analysis was used to identify Val762Ala polymorphism of the PARP-1.
In univariate analysis, PARP-1 762 AA genotype conferred a 3.4 fold reduction in risk (OR = 0.297, 95% CI = 0.105-0.813; P = 0.014), while heterozygous VA genotype conferred an even greater level of protection (OR = 0.06; 95%CI, 0.026-0.14; P < 10(-6)). In addition, wild type PARP-1 762 V allele had 5 times the risk of developing asthma than those without the allele (OR 0.199, CI 0.118-0.334, P = 10(-6)).
These findings suggest that PARP-1 V762A variants may be one of the factors participating in protection or susceptibility to asthma in our population.
已有研究表明，通过药物或基因敲除抑制聚（ADP - 核糖）聚合酶 -1（PARP -1），可在动物模型中为全身或组织炎症提供显著保护。本研究旨在分析PARP -1 Val762Ala多态性与土耳其成年哮喘患者的关联，该多态性据报道与酶活性降低有关。
共研究了112例病情稳定的哮喘患者和来自同一地理区域的180例正常对照，采用基于聚合酶链反应的限制性分析来鉴定PARP -1的Val762Ala多态性。
在单因素分析中，PARP -1 762 AA基因型使风险降低了3.4倍（OR = 0.297，95% CI = 0.105 - 0.813；P = 0.014），而杂合子VA基因型提供了更高水平的保护（OR = 0.06；95%CI，0.026 - 0.14；P < 10(-6)）。此外，野生型PARP -1 762 V等位基因发生哮喘的风险是无该等位基因者的5倍（OR 0.199，CI 0.118 - 0.334，P = 10(-6)）。
这些发现表明，PARP -1 V762A变体可能是参与我们人群中哮喘保护或易感性的因素之一。
